Blue Zone Wealth Advisors LLC Buys 1,727 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Blue Zone Wealth Advisors LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 18.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 11,301 shares of the company's stock after acquiring an additional 1,727 shares during the period. Blue Zone Wealth Advisors LLC's holdings in IDEXX Laboratories were worth $4,746,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Financial Advocates Investment Management increased its position in shares of IDEXX Laboratories by 28.7% in the 4th quarter. Financial Advocates Investment Management now owns 1,008 shares of the company's stock valued at $417,000 after buying an additional 225 shares in the last quarter. Silver Oak Securities Incorporated increased its position in shares of IDEXX Laboratories by 84.0% in the 4th quarter. Silver Oak Securities Incorporated now owns 631 shares of the company's stock valued at $260,000 after buying an additional 288 shares in the last quarter. 1900 Wealth Management LLC increased its position in shares of IDEXX Laboratories by 6.9% in the 4th quarter. 1900 Wealth Management LLC now owns 775 shares of the company's stock valued at $320,000 after buying an additional 50 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of IDEXX Laboratories by 0.5% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 198,450 shares of the company's stock valued at $82,047,000 after buying an additional 916 shares in the last quarter. Finally, Lecap Asset Management Ltd. increased its position in shares of IDEXX Laboratories by 587.7% in the 4th quarter. Lecap Asset Management Ltd. now owns 5,701 shares of the company's stock valued at $2,357,000 after buying an additional 4,872 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. Morgan Stanley increased their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Stifel Nicolaus increased their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, Piper Sandler increased their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $536.00.

IDEXX Laboratories Trading Up 0.5%

Shares of IDEXX Laboratories stock traded up $2.70 during midday trading on Friday, reaching $524.91. The company had a trading volume of 265,338 shares, compared to its average volume of 651,744. The firm has a market cap of $42.21 billion, a PE ratio of 49.19, a P/E/G ratio of 3.41 and a beta of 1.55. The stock has a fifty day moving average price of $460.16 and a 200 day moving average price of $440.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.71 earnings per share. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now directly owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.